相似文献
1
ASO Author Reflections: Disparate Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Based on Insurance Status.
Ann Surg Oncol. 2022 Jan;29(1):260-261. doi: 10.1245/s10434-021-10748-x. Epub 2021 Aug 28.
2
ASO Author Reflections: Evaluating Conversion of Low-Grade to High-Grade Appendiceal Neoplasms for Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Ann Surg Oncol. 2022 Jan;29(1):212-213. doi: 10.1245/s10434-021-10717-4. Epub 2021 Sep 1.
3
ASO Author Reflections: Significance of Primary Tumor Location and Genomic Alterations in Colorectal Peritoneal Metastases and Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy.
Ann Surg Oncol. 2023 Jul;30(7):4471-4472. doi: 10.1245/s10434-023-13522-3. Epub 2023 Apr 27.
4
ASO Author Reflections: When is the Best Time to Perform Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Recurrent Low-Grade Appendiceal Mucinous Neoplasm?
Ann Surg Oncol. 2022 Jun;29(6):3432-3433. doi: 10.1245/s10434-022-11515-2. Epub 2022 Mar 7.
5
ASO Author Reflections: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Ann Surg Oncol. 2022 Jun;29(6):3418-3419. doi: 10.1245/s10434-021-11057-z. Epub 2021 Nov 6.
6
ASO Author Reflections: Augmenting Clinical Decision-Making Around Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Through Traditional and Machine Learning Algorithms.
Ann Surg Oncol. 2023 Sep;30(9):5443-5444. doi: 10.1245/s10434-023-13716-9. Epub 2023 Jun 2.
7
ASO Author Reflections: Thirty Years of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Wake Forest University.
Ann Surg Oncol. 2022 Jun;29(6):3446-3447. doi: 10.1245/s10434-022-11514-3. Epub 2022 Mar 11.
8
ASO Author Reflections: Organ-Specific Adverse Effects After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy-A Scoping Review.
Ann Surg Oncol. 2022 Sep;29(9):6084-6085. doi: 10.1245/s10434-022-11426-2. Epub 2022 Feb 21.
9
ASO Author Reflections: Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-Analysis.
Ann Surg Oncol. 2022 Nov;29(12):7538-7539. doi: 10.1245/s10434-022-12317-2. Epub 2022 Jul 30.
10
ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Ann Surg Oncol. 2022 Oct;29(11):6577-6578. doi: 10.1245/s10434-022-11842-4. Epub 2022 Apr 29.
引用本文的文献
1
ASO Author Reflections: Is it Time for a Tailored Approach to Venous Thromboembolism Prophylaxis in Patients with Esophagogastric Cancer?
Ann Surg Oncol. 2022 Mar 14. doi: 10.1245/s10434-022-11529-w.
本文引用的文献
1
Impact of Insurance Status on Oncologic and Perioperative Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Ann Surg Oncol. 2022 Jan;29(1):253-259. doi: 10.1245/s10434-021-10670-2. Epub 2021 Aug 25.
2
Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology.
Gynecol Oncol. 2019 Oct;155(1):93-97. doi: 10.1016/j.ygyno.2019.08.013. Epub 2019 Sep 3.
3
Effect of insurance status on the stage of breast and colorectal cancers in a safety-net hospital.
J Oncol Pract. 2012 May;8(3 Suppl):16s-21s. doi: 10.1200/JOP.2012.000542.
4
The impact of health insurance status on the survival of patients with head and neck cancer.
Cancer. 2010 Jan 15;116(2):476-85. doi: 10.1002/cncr.24774.
Zotero 插件